3. Liu SY, et al. The Unique Characteristics of MET Exon 14 Mutation in Chinese Patients with NSCLC. J Thorac Oncol. 2016 Sep;11(9):1503-10. 4. Furqan M, et al. Effectiveness of standard treatments in non-smal...
JTO Clinical and Research Reports杂志2024年2月发表了一篇题为Cabozantinib response in a patient with NSCLC harboring both MET exon 14 skipping mutation and secondary RET fusion: a case report的文章,讲述了一个因MET突变产生...
[1].Gow CH, Hsieh MS, Wu SG, et al. A comprehensive analysis of clinical outcomes in lung cancer patients harboring a MET exon 14 skipping mutation compared to other driver mutations in an East A sian population. Lung Cancer, 2017, 103: 82-89. [2].Liu X , Jia Y, Stoopler M B,...
EXON 14 SKIPPING MUTATION 首页/癌基因/MET/ EXON 14 SKIPPING MUTATION MET基因编码的蛋白为肝细胞生长因子受体HGFR,具有酪氨酸激酶活性,与多种癌基因产物和调节蛋白相关,参与细胞信息传导、细胞骨架重排的调控,是细胞增殖、分化和运动的重要因素。目前认为,c-met与多种癌的发生和转移密切相关,研究表明,许多肿瘤病人...
因此,对于有Met外显子14突变的患者,即使是PD-L1强阳性,依然推荐靶向治疗。 责任编辑:觅健科普君 参考来源: 1.沃利替尼治疗MET外显子14跳变非小细胞肺癌患者的II期研究:初步疗效和安全性结果。摘要5707,2019 CSCO. 2.Lee GD, Lee SE, Oh DY. MET Exon 14 Skipping Mutations in Lung. J Thorac Oncol. ...
2023年10月，Drug Target Insights杂志发表了一篇题为《Optimal treatment for metastatic non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutation》的文章，这篇病例报告详细介绍了一位罹患携带METex14突变的转移性NSCLC，并检测出高PD-L1表达（肿瘤比例得分≥50%）的86岁老年男性患者。该患者接受了...
1. Paik PK, Felip E, et al. Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. N Engl J Med. 2020 Sep 3;383(10):931-943. 2. Wolf J, Seto T, et al. Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. N Engl J Med. ...
MET外显子14跳变的非小细胞肺癌 二线 MET exon 14 skipping mutation 1 Tepotinib 襯範顧願壓衊齋獵鏇鏇(網願積願網網鬱廠憲築) = 醖遞鏇選鹹鑰觸鹽製廠 齋壓鑰餘選願範顧壓襯 (願膚衊網蓋衊遞鹽鬱襯 ) 积极 2024-01-01 Vebreltinib 襯範顧願壓衊齋獵鏇鏇(網願積願網網鬱廠憲築) = 淵鹽...
MET exon 14 skipping mutations are emerging as a particularly promising biomarker, at least in the context of lung cancer. Ravi Salgia, MD, PhD Despite a strong rationale for targeting the tyrosine kinase receptor MET, drug development has proved fraught with challenges. Finding biomark...
Results Out of 1,934 advanced, non-squamous and never-smoking squamous NSCLC patients tested, 41 patients were found to have MET exon 14 skipping (2.1%). MET alteration types: 2% CBL binding-domain mutations, 34% poly-pyrimidine tract deletions, 63% splice donor mutations or deletions. The ...